医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LCT’s NTCELL® Parkinson’s Trial Results to Be Presented in Berlin

2016年06月23日 PM03:25
このエントリーをはてなブックマークに追加


 

SYDNEY & AUCKLAND, New Zealand

As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled “Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up” takes place at 12 noon Berlin time today.

Dr Snow, Principal Investigator for the trial, said, “This data shows a striking and significant improvement in all measurements of Parkinson’s disease in the four patients. Everything we measured has improved.”

Dr Ken Taylor, CEO of LCT, said, “The results of this clinical trial are consistent with what LCT has found in pre-clinical studies. Moreover microarray analyses identified that several nerve growth factors and nerve protective agents are released from NTCELL and this may explain the improvement observed in all of the measurements of Parkinson’s disease.”

The poster is available to view here.

For further information: www.lctglobal.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160622006576/en/

CONTACT

At the Company:
Ken Taylor, +64 9 276 2690
Chief
Executive
Mobile: +64 21 796 000
ktaylor@lctglobal.com
or
Media
Contact:

Botica Butler Raudon Partners
Rachael Joel, +64 9
303 3862
Mobile: +64 21 403 504
rachaelj@botica.co.nz

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • フェリング・ファーマシューティカルズ:夜中のトイレ起きは質の悪い睡眠の最大の原因であると専門家らが世界睡眠デーで指摘
  • GI Dynamics to Release 2016 Annual Report and Host Webcast for Year Ending 31 December 2016
  • Primary Health Care Limited (Primary) Signs Deal to Deploy Intelerad Medical Imaging Software Platform
  • Watts Sponsors Water Filtration Tower at Elementary School in the Philippines on World Water Day
  • Alexion Submits Application in Japan for Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)